FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000237324> ?p ?o ?g. }

• W2000237324 endingPage "469" @default.
• W2000237324 startingPage "461" @default.
• W2000237324 abstract "Affibody molecules are a recently developed class of targeting proteins based on a nonimmunoglobulin scaffold. The small size (7 kDa) and subnanomolar affinity of Affibody molecules enables high-contrast imaging of tumor-associated molecular targets, particularly human epidermal growth factor receptor type 2 (HER2). (99m)Tc as a label offers advantages in clinical practice, and earlier studies demonstrated that (99m)Tc-labeled recombinant Affibody molecules with a C-terminal cysteine could be used for HER2 imaging. However, the renal retention of radioactivity exceeded tumor uptake, which might complicate imaging of metastases in the lumbar region. The aim of this study was to develop an agent with low renal uptake and preserved tumor targeting.A series of recombinant derivatives of the HER2-binding Z(HER2)(:342) Affibody molecule with a C-terminal chelating sequence, -GXXC (X denoting glycine, serine, lysine, or glutamate), was designed. The constructs were labeled with (99m)Tc and evaluated in vitro and in vivo.All variants were stably labeled with (99m)Tc, with preserved capacity to bind specifically to HER2-expressing cells in vitro and in vivo. The composition of the chelating sequence had a clear influence on the cellular processing and biodistribution properties of the Affibody molecules. The best variant, (99m)Tc-Z(HER2)(:V2), with the C-terminal chelating sequence -GGGC, provided the lowest radioactivity retention in all normal organs and tissues including the kidneys. (99m)Tc-Z(HER2)(:V2) displayed high uptake of radioactivity in HER2-expressing xenografts, 22.6 ± 4.0 and 7.7 ± 1.5 percentage injected activity per gram of tissue at 4 h after injection in SKOV-3 (high HER2 expression) and DU-145 (low HER2 expression) tumors, respectively. In both models, the tumor uptake exceeded the renal uptake.These results demonstrate that the biodistribution properties of recombinant (99m)Tc-labeled Affibody molecules can be optimized by modification of the C-terminal cysteine-containing chelating sequence. (99m)Tc-Z(HER2)(:V2) is a promising candidate for further development as a diagnostic radiopharmaceutical for imaging of HER2-expressing tumors. These results may be useful for the development of imaging agents based on other Affibody molecules and, hopefully, other scaffolds." @default.
• W2000237324 created "2016-06-24" @default.
• W2000237324 creator A5014071440 @default.
• W2000237324 creator A5029027915 @default.
• W2000237324 creator A5029746497 @default.
• W2000237324 creator A5031153746 @default.
• W2000237324 creator A5038492787 @default.
• W2000237324 creator A5051852856 @default.
• W2000237324 creator A5065484939 @default.
• W2000237324 creator A5090698986 @default.
• W2000237324 date "2011-02-14" @default.
• W2000237324 modified "2023-10-16" @default.
• W2000237324 title "Molecular Design and Optimization of ^99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties" @default.
• W2000237324 cites W1965040263 @default.
• W2000237324 cites W1975730315 @default.
• W2000237324 cites W1983031498 @default.
• W2000237324 cites W1994040531 @default.
• W2000237324 cites W1994864308 @default.
• W2000237324 cites W1996076468 @default.
• W2000237324 cites W1998315961 @default.
• W2000237324 cites W2027617390 @default.
• W2000237324 cites W2029817996 @default.
• W2000237324 cites W2030008772 @default.
• W2000237324 cites W2031767134 @default.
• W2000237324 cites W2038126486 @default.
• W2000237324 cites W2038859765 @default.
• W2000237324 cites W2040531770 @default.
• W2000237324 cites W2044957636 @default.
• W2000237324 cites W2049067964 @default.
• W2000237324 cites W2049109062 @default.
• W2000237324 cites W2063823414 @default.
• W2000237324 cites W2066060629 @default.
• W2000237324 cites W2077787026 @default.
• W2000237324 cites W2079688396 @default.
• W2000237324 cites W2087909560 @default.
• W2000237324 cites W2096161857 @default.
• W2000237324 cites W2109874946 @default.
• W2000237324 cites W2112328645 @default.
• W2000237324 cites W2116667571 @default.
• W2000237324 cites W2127373124 @default.
• W2000237324 cites W2134450909 @default.
• W2000237324 cites W2149208272 @default.
• W2000237324 cites W2153565541 @default.
• W2000237324 cites W2153910988 @default.
• W2000237324 cites W2160125502 @default.
• W2000237324 cites W2161551116 @default.
• W2000237324 cites W2166148619 @default.
• W2000237324 cites W3024133487 @default.
• W2000237324 doi "https://doi.org/10.2967/jnumed.110.083592" @default.
• W2000237324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21321280" @default.
• W2000237324 hasPublicationYear "2011" @default.
• W2000237324 type Work @default.
• W2000237324 sameAs 2000237324 @default.
• W2000237324 citedByCount "84" @default.
• W2000237324 countsByYear W20002373242012 @default.
• W2000237324 countsByYear W20002373242013 @default.
• W2000237324 countsByYear W20002373242014 @default.
• W2000237324 countsByYear W20002373242015 @default.
• W2000237324 countsByYear W20002373242016 @default.
• W2000237324 countsByYear W20002373242017 @default.
• W2000237324 countsByYear W20002373242018 @default.
• W2000237324 countsByYear W20002373242019 @default.
• W2000237324 countsByYear W20002373242020 @default.
• W2000237324 countsByYear W20002373242021 @default.
• W2000237324 countsByYear W20002373242022 @default.
• W2000237324 countsByYear W20002373242023 @default.
• W2000237324 crossrefType "journal-article" @default.
• W2000237324 hasAuthorship W2000237324A5014071440 @default.
• W2000237324 hasAuthorship W2000237324A5029027915 @default.
• W2000237324 hasAuthorship W2000237324A5029746497 @default.
• W2000237324 hasAuthorship W2000237324A5031153746 @default.
• W2000237324 hasAuthorship W2000237324A5038492787 @default.
• W2000237324 hasAuthorship W2000237324A5051852856 @default.
• W2000237324 hasAuthorship W2000237324A5065484939 @default.
• W2000237324 hasAuthorship W2000237324A5090698986 @default.
• W2000237324 hasBestOaLocation W20002373241 @default.
• W2000237324 hasConcept C104317684 @default.
• W2000237324 hasConcept C12554922 @default.
• W2000237324 hasConcept C136339569 @default.
• W2000237324 hasConcept C150903083 @default.
• W2000237324 hasConcept C153911025 @default.
• W2000237324 hasConcept C161624437 @default.
• W2000237324 hasConcept C185592680 @default.
• W2000237324 hasConcept C202751555 @default.
• W2000237324 hasConcept C207001950 @default.
• W2000237324 hasConcept C2777807558 @default.
• W2000237324 hasConcept C2778172261 @default.
• W2000237324 hasConcept C40767141 @default.
• W2000237324 hasConcept C55493867 @default.
• W2000237324 hasConcept C86803240 @default.
• W2000237324 hasConceptScore W2000237324C104317684 @default.
• W2000237324 hasConceptScore W2000237324C12554922 @default.
• W2000237324 hasConceptScore W2000237324C136339569 @default.
• W2000237324 hasConceptScore W2000237324C150903083 @default.
• W2000237324 hasConceptScore W2000237324C153911025 @default.
• W2000237324 hasConceptScore W2000237324C161624437 @default.
• W2000237324 hasConceptScore W2000237324C185592680 @default.
• W2000237324 hasConceptScore W2000237324C202751555 @default.

• next